Pages
- Home
- Library technologies
- Partnering, Collaboration & Pipeline
- Antibody Discovery
- Company
- Project design & Licensing
- Bioinformatics / YUcare
- Contract Research
- Antibody Engineering
- Antibody Humanization
- Events
- News
- Legal notice
- Disclaimer
- Terms and conditions
- Sitemap
- Directions
- New Technologies
Posts by category
- Category: Allgemein
- Category: Events
- Category: Events Archive
- Category: Homepage Teaser
- Category: News
- CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program
- Innovation Award for CORAT’s COVID-19 antibody development
- CORAT’s human COVID-19 antibody ready for clinical trials
- Mechanism of action for human SARS-CoV-2 antibody COR-101 identified
- Human SARS-CoV-2 antibody COR-101 shows high efficacy in animal model
- COVID-19: First SARS-CoV-2 neutralizing antibody discovered
- COVID-19: Media coverage of YUMAB’s activities
- COVID-19: Lower Saxony’s health minister visits YUMAB
- YUMAB partner Enleofen enters joint development with Boehringer Ingelheim
- COVID-19: First step towards antibody therapy
- COVID-19: Media coverage of YUMAB’s activities – Archive
- Category: News Archive
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17